Đăng xuất
The tablets need to be swallowed with a glass of liquid.
Patients with hepatic impairment and renal impairment: adjustment of the dose is recommended (see 'Patients with moderate to severe renal impairment' as follows).
Patients with hepatic impairment: Adults and children over 6 years old: 5 mg once daily.
Oral Solution:Adults: 10 mg (10 ml of oral solution) once daily.
A 5 mg starting dose (5 ml of oral solution) may be proposed if this leads to satisfactory control of the symptoms.
Children: Children aged from 2 to 6 years: 2.5 mg (2.5 ml of oral solution) twice daily.
Children aged from 6 to 12 years: 5 mg (5 ml of oral solution) twice daily.
Children over 12 years of age: 10 mg (10 ml of oral solution) once daily.
The solution can be swallowed as such.
Hepatic impairment: No dose adjustment is needed in patients with solely hepatic impairment.
Patients with hepatic impairment and renal impairment: Dose adjustment is recommended (see Patients with moderate to severe renal impairment as follows).
Film-coated tablet and Oral solution: Elderly: Data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function is normal.
Patients with moderate to severe renal impairment: The dosing intervals must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula: (See equation.)
Click on icon to see table/diagram/imageDosing adjustments for Adult Patients with Impaired renal function: (See Table 1.)
Click on icon to see table/diagram/imageIn paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient, his age and his body weight.
